Formulation and Characterization of Epalrestat-Loaded Polysorbate 60 Cationic Niosomes for Ocular Delivery

Oleogels for the ocular delivery of epalrestat: formulation, in vitro, in ovo, ex vivo and in vivo evaluation

The ocular administration of lipophilic and labile drugs such as epalrestat, an aldose reductase inhibitor with potential for diabetic retinopathy treatment, demands the development of topical delivery systems capable of providing sufficient ocular bioavailability. The aim of this work was to develop non-aqueous oleogels based on soybean oil and gelators from natural and sustainable sources (ethyl cellulose, beeswax and cocoa butter) and to assess their reproducibility, safety and efficiency in epalrestat release and permeation both ex vivo and in vivo. Binary combinations of gelators at 10% w/w resulted in solid oleogels (oleorods), while single gelator oleogels at 5% w/w remained liquid at room temperature, with most of the oleogels displaying shear thinning behavior. The oleorods released up to 4 µg epalrestat per mg of oleorod in a sustained or burst pattern depending on the gelator (approx. 10% dose in 24 h). The HET-CAM assay indicated that oleogel formulations did not induce ocular irritation and were safe for topical ocular administration. Corneal and scleral ex vivo assays evidenced the permeation of epalrestat from the oleorods up to 4 and 2.5 µg/cm2 after six hours, respectively. Finally, the capacity of the developed oleogels to sustain release and provide significant amounts of epalrestat to the ocular tissues was demonstrated in vivo against aqueous-based niosomes and micelles formulations loaded with the same drug concentration. Overall, the gathered information provides valuable insights into the development of oleogels for ocular drug delivery, emphasizing their safety and controlled release capabilities, which have implications for the treatment of diabetic neuropathy and other ocular conditions.

Improving the Stability, Water Solubility, and Antioxidant Activity of α-Tocopherol by Encapsulating It into Niosomes Modified with Cationic Carbamate-Containing Surfactants

The low solubility of α-tocopherol in water and its susceptibility to photodegradation make it difficult for biological systems to absorb this natural antioxidant. To overcome these limitations, α-tocopherol was encapsulated in low-toxicity nanocontainers, namely, niosomes based on Tween 80 and cholesterol. The niosomes were modified with cationic surfactants containing a carbamate fragment. The size and charge of the particles were determined and their stability was assessed using dynamic and electrophoretic light scattering methods. It was found that the introduction of cationic surfactants to niosome formulations significantly improved their physicochemical properties and increased stability due to a positive charge of up to +40 mV being generated. Modified niosomes loaded with α-tocopherol were characterized by a hydrodynamic diameter of 100-120 nm, a narrow particle size distribution, and a high encapsulation efficiency of more than 90%. Testing the photochemical stability of α-tocopherol using a spectrophotometric method demonstrated that niosomes were able to protect this substance from UV irradiation. Luminescence analysis showed that the inclusion of α-tocopherol in niosomes increased their antioxidant activity by 30%. An acute toxicity study has demonstrated the safety of the systems. The LD50 value for niosomes modified with carbamate-containing surfactants and loaded with α-tocopherol exceeded 10,000 mg·kg-1 (mice, intraperitoneal and oral administration).

An update on the latest strategies in retinal drug delivery

INTRODUCTION

Retinal drug delivery has witnessed significant advancements in recent years, mainly driven by the prevalence of retinal diseases and the need for more efficient and patient-friendly treatment strategies.

AREAS COVERED

Advancements in nanotechnology have introduced novel drug delivery platforms to improve bioavailability and provide controlled/targeted delivery to specific retinal layers. This review highlights various treatment options for retinal diseases. Additionally, diverse strategies aimed at enhancing delivery of small molecules and antibodies to the posterior segment such as implants, polymeric nanoparticles, liposomes, niosomes, microneedles, iontophoresis and mixed micelles were emphasized. A comprehensive overview of the special technologies currently under clinical trials or already in the clinic was provided.

EXPERT OPINION

Ideally, drug delivery system for treating retinal diseases should be less invasive in nature and exhibit sustained release up to several months. Though topical administration in the form of eye drops offers better patient compliance, its clinical utility is limited by nature of the drug. There is a wide range of delivery platforms available, however, it is not easy to modify any single platform to accommodate all types of drugs. Coordinated efforts between ophthalmologists and drug delivery scientists are necessary while developing therapeutic compounds, right from their inception.

Lage E, Casas M, Concheiro A, Alvarez-Lorenzo C. Langmuir monolayer studies of non-ionic surfactants and DOTMA for the design of ophthalmic niosomes

The worldwide increase in diabetes entails a rise in associated diseases, with diabetic retinopathy on the forefront of the ocular complications. To overcome the challenges posed by ocular barriers, self-assembled nanocarriers have gathered increasing attention in recent years, with niosomes revealing themselves to be suitable for the delivery of a variety of drugs. This study investigated the mechanical properties of Langmuir monolayers comprising cholesterol, Tween 60, and 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA), both individually and in binary and ternary systems. The cholesterol monolayer was characterized by an L-shaped isotherm, reflecting two surface aggregation states. Tween 60 exhibited expanded conformation and progressive aggregation, transitioning through a phase change. The addition of cholesterol to Tween 60 resulted in a subtle reduction in surface compressional modulus. The compression isotherms highlighted the stabilizing effect of cholesterol on the monolayer, affecting the film's resistance to compression. The introduction of DOTMA in Tween 60 monolayers revealed concentration-dependent effects, where the compression resistance of the film was proportional to DOTMA concentration. Ternary systems of cholesterol, DOTMA and Tween 60 exhibited unique behavior, with DOTMA enhancing film stability and cholesterol modulating this effect. Temperature and subphase ionic strength variations further exacerbated the effects of DOTMA concentration. Brewster Angle Microscopy confirmed the absence of microdomains in the compressed monolayer, supporting the hypothesis of a monolayer collapse. Overall, the research provided valuable insights into the intricate interactions and mechanical behavior of these surfactant systems and the feasibility of obtaining cationic niosome-based drug delivery.

A Comprehensive Review on Niosomes as a Strategy in Targeted Drug Delivery: Pharmaceutical, and Herbal Cosmetic Applications

Niosomes are newly developed, self-assembling sac-like transporters that deliver medication at a specific site in a focused manner, increasing availability in the body and prolonging healing effects. Niosome discovery has increased drugs' therapeutic effectiveness while also reducing adverse effects. This article aims to concentrate on the increase in the worldwide utilization of niosomal formulation. This overview presents a thorough perspective of niosomal investigation up until now, encompassing categories and production techniques, their significance in pharmaceutical transportation, and cosmetic use. The thorough literature review revealed that extensive attention has been given to developing nanocarriers for drug delivery as they hold immense endeavor to attain targeted delivery to the affected area simultaneously shielding the adjacent healthy tissue. Many reviews and research papers have been published that demonstrate the interest of scientists in niosomes. Phytoconstituents, which possess antioxidant, antibiotic, anti-inflammatory, wound healing, anti-acne, and skin whitening properties, are also encapsulated into niosome. Their flexibility allows for the incorporation of various therapeutic agents, including small molecules, proteins, and peptides making them adaptable for different types of drugs. Niosomes can be modified with ligands, enhancing their targeting capabilities. A flexible drug delivery mechanism provided by non-ionic vesicles, which are self-assembling vesicular nano-carriers created from hydrating non-ionic surfactant, cholesterol, or amphiphilic compounds along comprehensive applications such as transdermal and brain-targeted delivery.

Overview of Recent Advances in Nano-Based Ocular Drug Delivery

Ocular diseases profoundly impact patients' vision and overall quality of life globally. However, effective ocular drug delivery presents formidable challenges within clinical pharmacology and biomaterial science, primarily due to the intricate anatomical and physiological barriers unique to the eye. In this comprehensive review, we aim to shed light on the anatomical and physiological features of the eye, emphasizing the natural barriers it presents to drug administration. Our goal is to provide a thorough overview of various characteristics inherent to each nano-based drug delivery system. These encompass nanomicelles, nanoparticles, nanosuspensions, nanoemulsions, microemulsions, nanofibers, dendrimers, liposomes, niosomes, nanowafers, contact lenses, hydrogels, microneedles, and innovative gene therapy approaches employing nano-based ocular delivery techniques. We delve into the biology and methodology of these systems, introducing their clinical applications over the past decade. Furthermore, we discuss the advantages and challenges illuminated by recent studies. While nano-based drug delivery systems for ophthalmic formulations are gaining increasing attention, further research is imperative to address potential safety and toxicity concerns.

Nanotechnology-based ocular drug delivery systems: recent advances and future prospects

Ocular drug delivery has constantly challenged ophthalmologists and drug delivery scientists due to various anatomical and physiological barriers. Static and dynamic ocular barriers prevent the entry of exogenous substances and impede therapeutic agents' active absorption. This review elaborates on the anatomy of the eye and the associated constraints. Followed by an illustration of some common ocular diseases, including glaucoma and their current clinical therapies, emphasizing the significance of drug therapy in treating ocular diseases. Subsequently, advances in ocular drug delivery modalities, especially nanotechnology-based ocular drug delivery systems, are recommended, and some typical research is highlighted. Based on the related research, systematic and comprehensive characterizations of the nanocarriers are summarized, hoping to assist with future research. Besides, we summarize the nanotechnology-based ophthalmic drugs currently on the market or still in clinical trials and the recent patents of nanocarriers. Finally, inspired by current trends and therapeutic concepts, we provide an insight into the challenges faced by novel ocular drug delivery systems and further put forward directions for future research. We hope this review can provide inspiration and motivation for better design and development of novel ophthalmic formulations.